The role of metabolic disorders in the risk of acute idiopathic deep venous thrombosis of the lower extremities development
Author Affiliations1State Budget Institution of Health of Novosibirsk region, City Clinical Hospital № 1 630075, Novosibirsk, Zalessky str., 6
2Novosibirsk Military Institute of Internal Troops named after General of the Army I.К. Yakovlev Ministry of Internal Affairs of Russia
3Institute for Internal and Preventive Medicine of SB RAMS 630090, Novosibirsk, Boris Bogatkov str., 175/1
Abstract
Acute thrombosis of deep veins of the lower extremities (ATDVLE) is one of the most frequent causes of death and disability in Russia and industrialized world. The term "risk factors" is an integral part of the modern concept of acute deep venous thrombosis of the lower extremities. It defines any states when there is or is supposed the cause-and-effect relationship between their presence and the increased frequency of illness occurrence. Studies in recent years have uncovered many hemostatic and hemodynamic mechanisms of development of thrombophilic states. It is known less about the role of the "metabolic syndrome" concept in the development of acute disorders of venous circulation in the lower extremities. 80 patients with ATDVLE aged 18 to 59 years (48.3 ± 1.5 years) (38 men and 42 women) were examined. The monitoring group of 580 people (360 men, 220 women; the average age of 49.9 ± 0.5 years) was selected from the population-based samples of the residents of two administrative districts of Novosibirsk and investigated in the framework of the project HAPIEE. The frequency of metabolic syndrome and its components according to the criteria of GFCF and IDF were defined in patients with ATDVLE. The reliable association of metabolic syndrome with ATDVLE was found. It was diagnosed in 53.8 % of the patients and 28,8. % of the control group people (p < 0.05). Among the metabolic syndrome components the independent risk factors for ATDVLE are lipid metabolism disorders characterized by rising concentrations of triglycerides to 1.7 mmol/l in 76.2 % of patients and in 22.2 % of control group people (p < 0.05), LDL cholesterol >of 3.0 mmol/l in 47.4 % of patients and 26.7 % in the control group (p < 0.05) and the reduction of the concentration of HDL cholesterol < 1,0 mmol/l in men; HDL cholesterol < a 1.2 mmol/l in women of 43.7 % of patients with ATDVLE and 10.0 % in the control group (p < 0.05).
Key words
References
- Baluda V.P., Baluda M.V., Goldberg A.P.,Б etc. Prethrombotic conditions. Thrombosis and its prophylaxis. М., 1999. (In Russian)
- Bokarev I.N., Popova L.V., Kozlova T.V. Thrombosis and antithrombotic therapy in clinical practice. М.: MIA, 2009. 23–27. (In Russian)
- Kryukov N.N., Kozupitsa G.N., Kryukov N.N. Obesity and metabolic syndrome. Samara: Parus, 2000. 160 p. (In Russian)
- Makatsariya A.D., Bitsadze V.O. Thrombophilic conditions in obstetrical practice. М.: Russo, 2001. 219–285. (In Russian)
- Mamedov M.N., Training school on diagnostics and treatment of hyperlipidemia (Handbook for physicians). М.: Profizer, 2007. 23–26. (In Russian)
- Oganov R.G., Maslennikova G.Ya. Cardio-vascular diseases prophylaxis – the real way to improve demographic situation in Russia. Kardiologiya. 2010. (1). 4–7. (In Russian)
- Suslina Z.A., Tanashyan M.M., Ionova V.G. Ischemic stroke: blood, vessel wall, antithrombotic therapy. М.: Medical book, 2005. 248 p. (In Russian)
- Shestakov M.V. Metabolic syndrome – real threat against population health around the world. Meditsynski vestnik. 2011. (15). 9–10. (In Russian)
- Braekkan S.K., Borch K.H., Mathiesen E.B. et al. Body height and risk of venous thromboembolism: The Tromsø Study // Am. J. Epidemiol. 2010. 171. 1109–1115.
- Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis // Thromb. Haemost. 1999. 81. (2). 165–176.
- Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey // JAMA. 2002. 287. 356–359.
- Franco R.F., Reitsma P.H. Genetic risk factors of venous thrombosis // Hum. Genet. 2001. 109. (4). 369–384.
- Grundy S.M., Cleeman J.I., Daniels S.R. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institutes cientific statement: Executive Summary // Crit. Pathw. Cardiol. 2005. 4. 198–203.
- Lakka H.M., Laaksonen D.E., Lakka T.A. et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men // JAMA. 2002. 288. 2709–2716.
- Rosendaal F.R. Venous thrombosis: a multi causal disease // Lancet. 1999. 353. (9159). 11.
- Steffen L.M., Cushman M., Peacock J.M. et al. Metabolic syndrome and risk of venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology // J. Thromb. Haemost. 2009. 7. 746–751.
About Authors (Correspondence):
Rоvenskikh D.N. - physician, surgeon-oncologist, e-mail: rovenskihd@mail.ru
Usov S.A. - doctor of medical sciences, professor
Voevoda M.I. - doctor of medical sciences, professor, corresponding member of RAS, director, e-mail: mvoevoda@ya.ru
Full Text